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Abstract: Krüppel-like factor 8 (KLF8) is a young member of the KLF transcription factor family proteins. It is highly
overexpressed in several types of human cancers and regulates various cellular processes important for tumor progression. Increasing evidence has made KLF8 a new focus in cancer research and a potential target for cancer therapy. This review highlights the role of KLF8 in cancer by summarizing the up-to-date studies into its structure, function as a dual transcription factor, target genes and mechanisms of expression and modifications.
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Introduction
There are 17 members in the KLF protein family. Many of them have been shown to play a
role in cancer [1]. Some of these transcription
factors act as transcriptional activators, some
act as transcriptional repressors and other
members have a dual role in both activating
and repressing gene expression. All of the KLF
proteins share three highly conserved Cys2His2
zinc finger motifs in DNA (CACCC GT-box or GCrich element) binding domain at their Cterminus with diverse N-terminal regulatory elements [2].
KLF8 possesses highly conserved zinc finger
domains at its C-terminus that binds to the
CACCC region of target gene promoters [3].
KLF8 was first reported as a transcriptional repressor of beta-globin gene expression [3]. It has
subsequently been identified as a critical regulator of cell proliferation, oncogenic transformation, epithelial to mesenchymal transition (EMT),
tumor invasion and metastasis. Although considered widely expressed, KLF8 expression is
barely detectable in most normal cell and tissue
types, but highly increased in a number of human cancer types. Thus, KLF8 has emerged as

an important cancer-regulating protein.
The structure of KLF8 protein
KLFs are named after homology with Krüppel
protein of Drosophila melanogaster. KLF8 is
present in most of the species. In human KLF8
is located in the chromosome X [4]. Human
KLF8 protein consists of 359 amino acid residues. It was first isolated from the K562 leukemia cell line [5]. A typical transcription factor
contains three essential domains for its activity,
1) a nuclear localization signal to transport the
protein into the nucleus, 2) a DNA binding domain to interact with promoter DNA and 3) a
transcriptionally regulatory domain to regulate
gene expression. The DNA binding domain is
highly conserved in all KLF proteins. In some
cases the Zinc finger domains also mediate
protein-protein interaction.
As depicted in Figure 1, KLF8 protein shares
with KLF3 and KLF12 a C-terminal binding protein (CtBP) interacting domain in its N-terminus
[3]. CtBP is a transcriptional co-repressor protein. The Pro-Val-Asp-Leu-Ser (PVDLS) motif (8690 aa) in KLF8 N-terminus is recognized by
CtBP. KLF8 interaction with CtBP triggers KLF8
transcriptional repression activity. Along with its
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transcriptional repression activity, KLF8 also
acts as a transcriptional activator [5, 6]. The
glutamine residues Q118 and Q248 of KLF8 are
essential for KLF8 transcriptional activation
function [7]. The two putative classical nuclear
localization signals (NLS) flanking the zinc finger
domains do not regulate KLF8 nuclear localization [8]. The post translational modifications
such as sumoylation and acetylation of KLF8 do
not appear to impact the nuclear localization of
KLF8, either. The serine 165 (S165) and lysine
171 (K171) residues of KLF8 are critical for its
nuclear localization. The C-terminal zinc finger
domains 1 and 2 bind to importin-beta, a protein which imports cytosolic proteins to the nucleus. The exact role of the S165 and K171
residues in regulating nuclear localization of
KLF8 remains to be determined. However, it is
speculated that PKC may phosphorylate KLF8
at the S165 residue, facilitating the localization
of the protein to the nucleus. Inhibition of PKC
activity by specific PKC inhibitor decreases the
nuclear localization of KLF8 [8]. These sites are
also important for cellular function of KLF8 as
KLF8 mutant without these regions failed to
activate cyclin D1 expression compared to wild
type KLF8 [8]. New DNA synthesis was also decreased in cells expressing these mutants. Poly
(ADP-Ribose) Polymerase 1 (PARP-1) is an important protein involved in DNA repair, post
translational modification known as PARylation,
DNA transcription, chromatin modeling and cancer progression [9-11]. PARP-1 has been widely
accepted as a therapeutic target for cancer
treatment [11]. Recently PARP-1 has been identified as a protein interacting with the Zn finger
motifs 1 and 2 of KLF8 [12]. This interaction
helps stabilize KLF8 protein in the nucleus. In
PARP-1 null cells KLF8 half-life is significantly
reduced and the level of ubiquitinated KLF8 is
significantly increased. KLF8 interaction with
and PARylation by PARP-1 is critical for its nuclear localization. PARP-1 interaction prevents
nuclear exporting protein CRM1 from binding to
KLF8 and thus inhibits KLF8 export out of the
nucleus. Inhibition of the interaction between
KLF8 and PARP-1 leads to the cytoplasmic localization of KLF8. It is believed to be caused by
increased KLF8 transport by CRM1 to the cytoplasm where KLF8 is ubiquitinated and subsequently degraded presumably by proteasome
[12]. Activation of cyclin D1 promoter by KLF8
was significantly reduced when PARP-1 was
knocked down or inhibited. KLF8 transcriptional
activity can be restored by re-expressing PARP-1
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Figure 1. Schematic structure of KLF8 protein. KLF8
interacts with the transcriptional co-repressor Cterminal binding protein (CtBP) through its repression domain (RD or PVDLS motif), with the transcriptional co-activators P300 and PCAF histone acetyltransferases through its activation domain (AD centered on Q118/Q248), with target DNA GT-box sequence via the three C2H2 zinc-finger (ZnF) motifs.
KLF8 also binds to importin through its nuclear localization signal sequences and PARP-1 at the ZnF region to regulate its nuclear localization. The acetylation sites and sumoylation site of KLF8 are also
shown.

in PARP-1 null cells indicating that KLF8 interaction with PARP-1 and PARylation in the nucleus
are crucial for KLF8 transcriptional activity and
cellular function [12] See Figure 1.
The expression and modifications of KLF8
Understanding the mechanisms behind the elevated expression of KLF8 in cancers is the key
to finding important signal pathways leading to
KLF8 activation in cancer. It has been reported
that KLF8 expression is regulated at both transcriptional and post-translational levels. KLF8
acts as the downstream target of FAK which,
activated by integrin signaling, enhances cell
proliferation, cell migration through several intermediate transducers such as Src and PI3K
[13]. KLF8 expression is highly elevated in FAK
over-expressing cells of both mouse and human
origins [5, 14]. Integrin-mediated cell adhesion
was also able to upregulate KLF8 expression.
These observations gave rise to an assumption
that KLF8 activates cyclin D1 to regulate cell
proliferation as a downstream mediator of FAK.
Subsequent studies demonstrated that the FAKdependent regulation of KLF8 is mediated by
SP1 transcription factor which activates KLF8
gene expression by directly binding and activating KLF8 gene promoter. The signaling from FAK
to SP1 is mediated by PI3K-AKT and ERK MAPkinase pathways [15]. KLF8 promoter contains
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GT- box (CACCC) regions, consensus binding
sites for KLF transcription factors. Indeed, KLF3
can directly repress whereas KLF1 directly activates KLF8 gene promoter [16]. In the presence
of these three KLF members, KLF8 transcription
is repressed by KLF3. In this context, KLF1 also
activates KLF3 transcription [16]. A recent study
has identified a cross-talk between Wnt and
KLF8 signaling to nuclear β-catenin function in
human liver cancer cells [17].
Post-translational modifications are an essential
mechanism for the regulation of protein expression and function. KLF8 can be modified by various such mechanims including sumoylation,
acetylation ubiquitylation and PARylation. KLF8
is sumoylated by small ubiquitin like modifiers
SUMO-1, SUMO-2, and SUMO-3, primarily by
SUMO-1. When sumoylated at Lys67, the function of KLF8 as a transcriptional activator or
repressor is limited. These results suggest that
KLF8 is sumoylated when its function is not
needed in the cell [6]. Acetylation was found to
be another important post-translational modification of KLF8. KLF8 is acetylated at lysine93,
lysine95 and lysine67 by histone acetyltransferase P300 and PCAF co-activators. Acetylation
at the Lysine93 is mediated by P300, whereas
acetylation at the lysine67 and lysine95 is mediated by both P300 and PCAF. Lysine67 is a
common site for both sumoylation and acetylation, thus the sumoylation and acetylation at the
lysine67 counteract each other [18]. CtBP recruits E2 and E3 ligase to enhance sumoylation
and thus it positively regulates sumoylation.
Acetylation at lysine93 and lysine95 inhibits
CtBP binding to KLF8 repression domain
(86PVDLS90) and thus indirectly inhibits sumoylation. Further using lysine67, lysine93, lysine
95 mutants it was proved that acetylation at
these sites promotes the cyclin D1 expression
and cell cycle progression by KLF8. A balance
between sumoylation and acetylation appears
to be critical for KLF8 function in cellular processes [18]. KLF8 PARylation by PARP-1 is a third
post translational modification which is required
for its transcriptional activity and localization in
nucleus to bind to gene promoters [12]. In the
absence of PARP-1 function, KLF8 undergoes
ubiquitylation and subsequent degradation presumably by proteasome in the cytoplasm [12].
Till date KLF8 phosphorylation has not been
well studied although it was predicted that
phosphorylation at Serine165 by PKC may play
a role in the nuclear localization and cellular
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function of KLF8. Treatment with PKC inhibitor
results in less nuclear localization of KLF8 and
a decrease in cyclin D1 expression [8].
KLF8 functions as a dual transcription factor
KLF8 was initially identified as a transcriptional
repressor [3]. KLF8 represses gene expression
through binding to a co-repressor CtBP to its
PVDLS domain (aa86-90). This domain is known
as repression domain (RD) (Figure 1) [3]. It was
also shown that KLF8 is widely expressed in all
human tissues. KLF8 was found to bind to
CACCC region or GT-box region of target gene
promoters. CtBP binding to the PVDLS domain
of KLF8 triggers its transcriptional repression of
beta-globin gene promoter reporter containing a
tandem of GT-boxes. Consistently, a systematic
screening for KLF proteins that bind and regulate gamma-globin gene promoter suggested
that KLF8 is a transcriptional repressor of
gamma-globin gene expression [19]. Interestingly, mutational disruption of the PVDLS domain could not completely abolish KLF8 transcriptional repressor activity suggesting that
KLF8 acts as a repressor in both CtBPdependent and independent manners [3]. KLF8
was then shown to be highly overexpressed in
FAK overexpressing cells and to transcriptionally
activate cyclin D1 gene promoter to promote
cell cycle progression [5]. KLF8 binds directly to
a GT-box on cyclin D1 promoter and activates its
expression [5]. KLF8 knockdown significantly
decreases cyclin D1 expression and the cell
cycle progression [5]. Later it was found that
KLF8 also activates gene expression by recruiting the co-activators P300 and PCAF to its activation domain containing the core residues of
Q118 and Q248 [7]. P300 and PCAF in turn
acetylate the histones to activate gene promoter [7]. Mutation in this KLF8 activation domain completely abolishes KLF8 transcriptional
activating activity. Both transcriptional activation and repression functions of KLF8 labeled it
as a dual transcription factor. KLF8 plays an
important role in cell proliferation as a dual
transcription factor by activating cyclin D1 expression [20-22]. KLF8 directly represses KLF4
expression to activate cell proliferation [6].
Given the tumor suppressor role of KLF4 [23],
repression of KLF4 by KLF8 could contribute to
tumor progression. KLF8 directly binds to a GTbox on E-cadherin promoter and represses its
activity [24, 25]. E-cadherin is a marker of
epithelial cells and a tumor suppressor [25],
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ing breast [24, 26, 28], ovarian [15, 28], renal [28, 29],
liver [17, 30], gastric [31]
and brain [20-22] cancer
(Figure 2). Various signaling
pathways regulating KLF8
and its target genes associated with cancer have been
identified (Figure 3). Initial
effort began with a study of
the role of KLF8 in oncogenic transformation of
NIH3T3 cells [28]. In that
report, tetracycline regulated inducible overexpression of KLF8 caused the
transforming phenotypes
including loss of contact
inhibition and serum indeFigure 2. KLF8 regulated human cancer types. Involved KLF8 target genes of
pendent growth [28]. On the
transcriptional activation (upward arrows) or repression (downward arrows) are
other hand, overexpression
indicated.
of a KLF8 inhibiting mutant
clearly reduces the ability of
v-Src to transform NIH3T3
cells and KLF8 regulation of cyclin D1 expresloss of its expression leads to loss of cell-cell
sion appears to play a partial role [28]. KLF8
contact resulting in epithelial to mesenchymal
directly represses the tumor suppressor gene
transition (EMT) which is a critical early step of
KLF4 which may also contribute to the transforcancer cell invasion and metastasis. Recently it
mation [6]. Cancer cells are benign when they
was found that KLF8 directly binds to GT-box 3
are localized in their origin. Cancer becomes
on MMP9 promoter and transcriptionally actimalignant when cancer cells invade the exvates its expression [26]. Matrix metalloprotracellular matrix and migrate to different locateinases (MMPs) are protease enzymes which
tions. This process is known as metastasis if the
break down the extracellular matrix proteins
cell migration takes the route of blood or lymph
and promote cell invasion into other tissues.
circulation. EMT is a process during which
Increase in MMP expression and catalytic activepithelial cells are transformed into fibroblastity leads to cancer cell invasion and metastasis.
like cells that are more motile and invasive [25].
Taken together, KLF8 appears to target tumor
EMT plays a critical role in tumor metastasis. On
suppressors for transcriptional repression and
one hand, EMT allows a few cancer cells to distumor promoting genes for transcriptional actisociate and migrate away from the primary tuvation for an overall effect favoring tumor promor mass. On the other hand, it renders the
gression. The downregulation of E-cadherin and
cancer cells ability to survive the circulation by
upregulation of N-cadherin, MMP 2 and 9 as
avoiding anoikis- an apoptotic process triggered
well as integrins have also been correlated to
by cell detachment from extracellular matrix
the expression of KLF8, along with the other
that kills particularly epithelial cells. Cancer cell
EMT-promoting factors including Snail, TWISTs
migration, invasion and metastasis are the most
and ZEBs, during the implantation stage of bomalignant stages of cancer. E-cadherin and
vine embryogenesis [27].
MMP9 are two of the most important mediators
in these stages. During EMT E-cadherin expresKLF8 in cancer
sion is decreased and the expression of mesenchymal markers such as N-cadherin and
Since the initial descriptions of KLF8 as a reguvimentin is increased. KLF8 directly represses E
lator of beta-globin and cyclin D1 transcription
-cadherin expression and triggers subsequent
[3, 5], several reports have been followed to
EMT process in both canine kidney epithelial
demonstrate the aberrant overexpression of
cell line MDCK and human mammary epithelial
KLF8 in various types of human cancer includ-
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vation of MMP2, the transcriptional repression of caspases 3
and 9 and activation of Bcl-xL [30].
Related to this study, a most recent report has suggested a role of
KLF8 in mediating Wnt to βcatenin signaling to activate the
transcription of c-Myc, cyclin D1
and Axin1 and promote HCC cell
proliferation [17]. In gastric cancer,
the KLF8 expression was found
highly elevated in gastric cancer
tissues from 80 patients and in
human gastric cancer cell lines
Figure 3. KLF8 signaling. Upstream regulators, downstream target
genes and cellular processes are shown.
compared to the adjacent nontumor gastric tissue and normal gastric epithelial cells [31]. KLF8
knockdown in the cancer cells resulted in recell line MCF-10A [24]. This induction of EMT by
duced xenografted tumor growth in nude mice
KLF8 does not appear to depend upon other
with decreased expression of cyclin D1 and BCL
EMT inducer proteins such as Snail. KLF8 di-2, the upregulation of P27 and Bax expression
rectly activates MMP9 gene promoter by binding
and apoptosis in the tumor cells [31]. The first
to a GT-box to increase MMP9 expression and
implication of the role of KLF8 in cancer was
catalytic activity [26]. KLF8 overexpression
from an early study in which the U-251MG huleads to increased breast cell migration and
man glioblastoma cells were used [14]. That
invasiveness. KLF8 knockdown in highly metasstudy showed that the expression of KLF8 in the
tatic breast cancer cell line significantly decells depends upon the expression and activity
creases the lung metastatic rate in nude
of FAK and correlated to the increase/decrease
mouse [26]. In ovarian cancer cells KLF8 transof cyclin D1/p27 and the cell cycle progression.
duces FAK to PI3K to AKT to SP1 signaling to
Subsequently, a recent study demonstrated that
upregulate cyclin D1 expression and enhance
the U251 glioblastoma cell growth can be inthe cell cycle progression [15]. The recent disducd to undergo apoptosis by knocking down
covery of PARP-1 binding to KLF8 in the nucleus
the expression of KLF8 [22]. In the meantime, a
in both breast and ovarian cells [12] suggests a
group from Germany reported the positive expotentially interesting cooperation between
pression of KLF8 in human gliomas of all grades
KLF8 and PARP-1 in these cancer cell types.
irrespective of the proliferation rate assumed by
Besides breast and ovarian cancer, role of KLF8
Ki67 staining, and knocking down KLF8 in the
has been identified in a few other cancer types.
U87-MG glioma cells dramatically inhibited the
It was reported that KLF8 protein and mRNA is
cell proliferation [21].
highly overexpressed in human renal cell carcinoma (RCC) tissues compared to that in the
In summary, studies to date have demonstrated
adjacent non-tumorous renal tissues [29]. Sia critical role of KLF8 in the regulation of a varilencing KLF8 expression in the RCC 786-0 cells
ety of cellular processes favoring tumor progresinduces apoptosis and inhibition of invasion in
sion of many cancer types. While this certainly
vitro and tumor growth in nude mice [29]. In
suggests that KLF8 could be used as a potential
human hepatocellular carcinomas (HCC), the
future molecular target for cancer therapy,
aberrant overexpression of KLF8 was correlated
many questions regarding the tumor-promoting
with the metastatic potential, post-surgical reor oncogenic role and mechanisms of KLF8 recurrence of the HCC tumors and poor survival
main to be answered by additional studies using
studied in more than 300 patient cases [30].
well-defined experimental systems such as nonUsing tissue microarray analysis of the patient
tumorigenic human cells of cancer origins and
specimens and several KLF8-genetically modiKLF8 genetically engineered mouse models.
fied HCC cell lines, the study demonstrated that
in HCC cells KLF8 promotes proliferation and
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